Chemoradiotherapy or chemotherapy as adjuvant treatment for resected gastric cancer: should we use selection criteria?
chemoradiotherapy
chemotherapy
gastric cancer
survival
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
05
2020
accepted:
08
02
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
The management of gastric adenocarcinoma is essentially based on surgery followed by adjuvant treatment. Adjuvant chemotherapy (CT) as well as chemoradiotherapy (CTRT) have proven their effectiveness in survival outcomes compared to surgery alone. However, there is little data comparing the two adjuvant approaches. This study aimed to compare the prognosis and survival outcomes of patients with gastric adenocarcinoma operated and treated by adjuvant radio-chemotherapy or chemotherapy. We retrospectively evaluated 80 patients with locally advanced gastric cancer (LGC) who received adjuvant treatment. We compared survival outcomes and patterns of recurrence of 53 patients treated by CTRT and those of 27 patients treated by CT. After a median follow-up of 38.48 months, CTRT resulted in a significant improvement of the 5-year PFS (60.9% There is a particular survival benefit of adding radiotherapy to chemotherapy in patients with selected criteria such as lymph node involvement, high LNR LVI, and PNI.
Sections du résumé
BACKGROUND
BACKGROUND
The management of gastric adenocarcinoma is essentially based on surgery followed by adjuvant treatment. Adjuvant chemotherapy (CT) as well as chemoradiotherapy (CTRT) have proven their effectiveness in survival outcomes compared to surgery alone. However, there is little data comparing the two adjuvant approaches. This study aimed to compare the prognosis and survival outcomes of patients with gastric adenocarcinoma operated and treated by adjuvant radio-chemotherapy or chemotherapy.
MATERIALS AND METHODS
METHODS
We retrospectively evaluated 80 patients with locally advanced gastric cancer (LGC) who received adjuvant treatment. We compared survival outcomes and patterns of recurrence of 53 patients treated by CTRT and those of 27 patients treated by CT.
RESULTS
RESULTS
After a median follow-up of 38.48 months, CTRT resulted in a significant improvement of the 5-year PFS (60.9%
CONCLUSION
CONCLUSIONS
There is a particular survival benefit of adding radiotherapy to chemotherapy in patients with selected criteria such as lymph node involvement, high LNR LVI, and PNI.
Identifiants
pubmed: 34211778
doi: 10.5603/RPOR.a2021.0040
pii: rpor-26-2-266
pmc: PMC8241305
doi:
Types de publication
Journal Article
Langues
eng
Pagination
266-280Informations de copyright
© 2021 Greater Poland Cancer Centre.
Déclaration de conflit d'intérêts
Conflicts of interest The authors declare no conflicts of interest.
Références
Radiat Oncol. 2012 Oct 15;7:169
pubmed: 23068190
World J Surg. 2004 Sep;28(9):866-9
pubmed: 15593458
Expert Rev Anticancer Ther. 2009 May;9(5):637-47
pubmed: 19445580
J Clin Oncol. 2012 Jan 20;30(3):268-73
pubmed: 22184384
J Clin Oncol. 2012 Jul 1;30(19):2327-33
pubmed: 22585691
Ann Surg. 2004 Nov;240(5):808-16
pubmed: 15492562
Semin Radiat Oncol. 2002 Apr;12(2):150-61
pubmed: 11979416
Oncotarget. 2016 May 24;7(21):31215-25
pubmed: 27145279
Ann Surg. 2007 Apr;245(4):543-52
pubmed: 17414602
World J Gastroenterol. 2014 Sep 28;20(36):12900-7
pubmed: 25278687
Tumori. 2002 Jan-Feb;88(1):21-7
pubmed: 12004845
Ann Surg Oncol. 2013 Jul;20(7):2317-27
pubmed: 23677605
Radiother Oncol. 2012 Sep;104(3):361-6
pubmed: 22985776
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
Ann Oncol. 2000 Jul;11(7):837-43
pubmed: 10997811
J Clin Oncol. 2015 Oct 1;33(28):3130-6
pubmed: 25559811
Gastric Cancer. 2011 Jun;14(2):113-23
pubmed: 21573742
Ann Surg Oncol. 2002 Apr;9(3):278-86
pubmed: 11923135
PLoS One. 2013 Oct 17;8(10):e76041
pubmed: 24146811
Eur J Surg. 2002;168(11):597-608
pubmed: 12699095
BMC Cancer. 2011 Aug 02;11:329
pubmed: 21810227
Radiother Oncol. 2012 Sep;104(3):367-73
pubmed: 22981610
N Engl J Med. 2007 Nov 1;357(18):1810-20
pubmed: 17978289
PLoS One. 2014 Feb 21;9(2):e88907
pubmed: 24586437
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):e585-92
pubmed: 22975616
J Clin Oncol. 2003 Oct 1;21(19):3647-50
pubmed: 14512396
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
World J Gastroenterol. 2016 Jan 21;22(3):1131-8
pubmed: 26811652
PLoS One. 2013 Jul 18;8(7):e68939
pubmed: 23874819
Gastric Cancer. 1998 Mar;1(2):125-133
pubmed: 11957056
N Engl J Med. 2001 Sep 6;345(10):725-30
pubmed: 11547741
Int J Oncol. 2010 Jun;36(6):1461-7
pubmed: 20428770
Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1357-62
pubmed: 2262358
J Clin Oncol. 2010 May 10;28(14):2430-6
pubmed: 20368551
Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001964
pubmed: 15495024
Ann Surg. 2005 Feb;241(2):247-55
pubmed: 15650634
Gastric Cancer. 1998 Dec;1(1):10-24
pubmed: 11957040
Radiother Oncol. 2015 Oct;117(1):171-7
pubmed: 26299196